Ren.Nu, a Dietary Program for Individuals with Autosomal-Dominant Polycystic Kidney Disease Implementing a Sustainable, Plant-Focused, Kidney-Safe, Ketogenic Approach with Avoidance of Renal Stressors
Abstract
:1. Introduction
2. Materials and Methods
2.1. Tools and Materials Used
2.2. Design and Features of the Ren.Nu Program
- Ketogenic intervention with low-carb/high fat diet and time-restricted eating to raise ketones and lower blood glucose/insulin.
- Plant-focused, alkaline diet with incorporation of some dairy, eggs, and fish.
- Limiting renal stressors oxalate, inorganic phosphate, and purines/uric acid to avoid renal injury by microcrystals.
- Nutrient-dense, whole foods and minimally processed foods.
- Remote participation for increased accessibility and scalability.
- Digital and online tools to facilitate participation, supervision, and sense of community.
- Education on scientific background and hands-on skills for implementation of diet and lifestyle changes.
- Tracking of nutrient intake and self-monitoring of health parameters to stay on track.
- Supervised and monitored by registered dietitian.
- Individualization, education, and practice allows long-term sustainability of diet and lifestyle changes.
- Serum ketone testing in the AM—prior to eating, 30–60 min after waking.
- Serum ketone testing in the PM—prior to eating dinner, ideally 2–3 h after the last food intake.
- Urine pH—measuring several times throughout the day using provided test paper.
- Body weight, blood pressure, and blood glucose were self-measured at the participant’s discretion.
3. Results
3.1. Design of the Ren.Nu Program
- Reduce net carbohydrate intake to lower blood glucose and insulin levels.
- Raise blood ketone levels.
- Avoid excessive consumption of the renal stressors oxalate, inorganic phosphate, and dietary protein acid precursors.
- Avoid the acidifying effect on urine pH and lowering of serum bicarbonate levels associated with heavy consumption of animal protein.
- Avoid heavy consumption of purine-rich meat to lower the burden of uric acid filtration and excretion by the kidneys.
- Support a nutrient-dense and diverse dietary intake with a focus on whole foods and minimally processed foods.
3.2. Beta Test of the Ren.Nu Program
3.3. Primary Outcomes of the Beta Test
3.3.1. Serious Adverse Events
3.3.2. Qualitative Findings
Satisfaction, Tolerability, and Effects on Health and Well-Being
- Health and Physical Wellness (n = 18 Unless Otherwise Noted).When asked about any changes with recurrent health issues experienced prior to starting the Ren.Nu program, respondents reported the biggest changes and improvements were regarding flank pain and fatigue (Table 2).In total, 50% (n = 9) of respondents “strongly agreed”, and 39% (n = 7) “somewhat agreed” that the Ren.Nu program improved their PKD symptoms. No participant disagreed (scale: 1 = strongly disagree, 5 = strongly agree) (Table 2).The most common new symptoms reported during the first 2 weeks of starting a PFKD were fatigue and brain fog. A total of 72% (n = 13) of respondents reported experiencing fatigue while 56% (n = 10) reported brain fog. After the initial 2 weeks, and a transition into ketosis, 85% (n = 11) of newly reported fatigue resolved and 100% (n = 10) of brain fog resolved.A total of 83% (n = 15) of respondents believed that the Ren.Nu program improved their overall health. The average level of belief was 4.8 on the agreement scale (1 = disagree, 5 = agree) (Table 2).There was also a high level of belief that the Ren.Nu program improved their “overall kidney health” with 83% (n = 15) of respondents agreeing at the highest level of 5. The average level of belief was 4.8 on the agreement scale (1 = disagree, 5 = agree) (Table 2).
- Dietary Satisfaction (n = 17 Unless Otherwise Noted).Overall satisfaction with the way they were eating while following a PFKD was rated high with participants. In total, 59% (n = 10) rated their diet satisfaction as a 4 and 36% (n = 6) liked their diet “very much”, the highest rating (scale: 1 = dislike extremely, 5 = like very much) (Table 2).Compared to how they ate prior to Ren.Nu vs. following a PFKD, 35% (n = 6) of respondents enjoyed their new pattern of eating better, and 29% (n = 5) enjoyed it “much better” (scale: 1 = I liked my previous eating pattern much better, 5 = I like my present eating pattern much better). Satisfaction with the amount of food eaten also ranked high. In total, 41% (n = 4) of respondents ranked satisfaction as a 4 and 35% (n = 6) ranked satisfaction as a 5 “very satisfied” (scale: 1 = not satisfied, 5 = very satisfied). When asked how their food tasted while following a PFKD, 41% (n = 7) of respondents ranked their satisfaction as “very satisfied”, and 41% (n = 7) ranked it at 4 on the satisfaction scale (scale: 1 = not satisfied, 5 = very satisfied).
- Curriculum and Ren.Nu Experience (n = 18 Unless Otherwise Noted).In total, 83% (n = 15) of respondents agreed that the nutrition curriculum content in the Ren.Nu program was easy to understand. The overall average was 4.8 on the agreement scale (1 = disagree, 5 = agree) (Table 2).Participants strongly agreed, with an average agreement response of 4.8, that the nutrition curriculum helped them make necessary dietary changes to preserve kidney function. A total of 94% (n = 17) of respondents agreed at the highest level of 5 (scale: 1 = disagree, 5 = agree) (Table 2).
- A Resilient Mindset and Overall Satisfaction.
Health and Physical Wellness |
---|
“Before joining the program, I was encountering daily flank pain, and fatigue. Now I have a new outlook on life, I feel empowered that the food I consume is going to help heal my body.” (Participant M7) “The kidney pain I experienced on a weekly, if not daily basis, has been reduced dramatically. I even sleep better because of it.” (Participant F11) “The Ren.Nu program has been beneficial to my kidneys and overall health because of the weekly PKD modules. I loved learning how certain foods hurt your kidneys and liked it even more when I learned about foods that are beneficial to kidney” (Participant F2) “Eating a plant-based keto diet that is lower protein has left me feeling better, emphasized the importance of diet and mindset in improving my health and given me hope that I am doing everything in my control to tackle my PKD.” (Participant F8) “I have learned more about how to best care for my kidney health in the past 12 weeks than I have learned in the past decade!” (Participant F11) “I feel like I have the tools and mindset to choose better foods from now on, knowing that my choices will help my kidneys continue to function longer.” (Participant F1) |
Dietary Satisfaction |
“The great meal suggestions and gradual transitions have made me feel very satisfied with my new diet and I finally feel like I can keep going with this plan.” (Participant F5) |
Curriculum and Ren.Nu Experience |
“I believe the instruction, support, and attention to detail that has been given throughout this program is unsurpassed.” (Participant F11) “The beta program made it very easy to switch to a new diet and set me up for success in the long run. I found the science-driven information in the program to be very educational and empowering.” (Participant F10) “The Ren.Nu program helped me to put the entire puzzle together. I needed more knowledge how to plan and make nutritional and healthy meals, and keto-friendly menu. I was lost on my own.” (Participant M5) |
Resilient Mindset and Overall Satisfaction |
“It taught me to think consciously about my meals. It gave me the confidence to ask restaurants what ingredients are in the menus.” (Participant M7) “I could follow recommendations more easily because I had tools to let go of stress and visualize creating healthier kidneys.” (Participant F1) “With the discussions and training, it felt like we had direction, insight, training, enthusiasm, and a place we could ask a lot of questions. The food chart and meal plans were amazing, and I am not sure I could have done it without those tools. Each week we have learned valuable new tools and information.” (Participant M6) “The Ren.Nu program breaks down the diet and health changes into manageable steps while giving us all the information and science behind their recommendations.” (Participant F8) I found the science-driven information in the program to be very educational and empowering.” (Participant F10) |
Feasibility |
“I am so incredibly grateful to the entire team who have put this research together in a way that I can actually put it into practice.” (Participant M6) “I am really glad that I started this program. I feel like even if I do half of the things I’ve learned about, I will improve my kidney health. This change was shockingly easier than expected.” (Participant F13) “This program goes far beyond just a ketogenic approach, has changed my eating habits and made these lifestyle changes feel sustainable long term.” (Participant F8) |
Overall Impact on Time and Routine |
“I go shopping every few days it seems (more often than I used to), and I probably spend 1–2 h a day with meal cooking (dinner is usually the most time-consuming). When I’m on it and think of a few meals ahead of time it is much smoother.” (Participant F8) “I have prepared a menu with my favorite meals that give my wife a really good idea of what to shop for and what we can make. This has been very helpful.” (Participant M6) |
Impact of Nutrient and Data Tracking |
Tracking was very time-consuming but I don’t know how to improve that. I understand that that level of data is needed.” (Participant M8) |
Biggest Barrier |
“Protein intake lowering and source of protein, this was difficult to do.” (Participant M10) “It was so much easier to eat meat to get protein than to figure out how to get enough in plant protein. However, I liked eating much less meat than I did before. It would have been much more difficult if I had never tried eating Keto before.” (Participant F1) “Eating too much protein” (Participant F13) “The low protein was and is honestly the hardest part for me—I try now if I go over on my protein level to make it all plant-based. I had no idea how much protein I was eating before and I think most Americans don’t and those who eat meat at every meal are well over 100 gms/day!” (Participant F8) |
Renal Function Measures |
“I have rigorously done this diet for two months now and my labs showed a steady improvement of my eGFR and my creatinine levels, making me the first family member with PKD to improve his kidney function ever, something unheard of.” (Participant F9) “I saw my first downward trend in creatinine (and improvement in GFR) in 5 years and I feel so much more excited for the future!” (Participant F8) |
Overall Participant Experience and Continued Support |
“The classes I was able to attend—feeling like I was part of a group and connecting to other PKD people, the one-on-one sessions, and the recipes/menus” (Participant F8) “Before this program, I hadn’t ever talked to anyone with PKD personally (besides for patients in the hospital) so it was great to see other “real” people who are facing the same issue I am.” (Participant F8) “The online classes and hearing the questions of classmates. I forgot that we all had PKD because I was so focused on the diet journey we were on! I loved being part of this community.” (Participant F1) “Hearing about other people’s experiences.” (Participant F12) “I loved hearing others ask the same questions I have each week and knowing I am not alone in this journey.” (Participant M6) “I also appreciated the community of PKD warriors that they are building that makes you feel less alone on this journey.” (Participant 10) “Some kind of personal or group check-in with one or all of you.” (Participant F9) “I would love to be able to stay in touch with the dietitians and people in this group in some way. I hope we can continue the smaller FB group and that the next ren.nu program group gets added. I also love the idea of monthly emails or the occasional recipe sent out and maybe organize a group check-in bi-annually to see how people are doing!” (Participant F8) “1 on 1 dietitian time, group facilitated discussions with other PKD beta testers so we can stay connected and learn from each other.” (Participant M10) “Keep supporting me with a quarterly/semi-annual follow-up.” (Participant M7) |
Feasibility
- Overall Impact on Time and RoutineHow eating a PFKD and tracking for the program affected participant’s time and routine and the financial impact were the two major themes represented in participant responses for feasibility. Participants reported that their eating habits did not interfere very much with their life activities on the feedback questionnaires (scale: 1 = very much, 5 = not at all). In total, 41% (n = 7) ranked their eating habits as a 4, having little impact. A fair number of respondents were neutral on the impact at 29.4% (n = 5). When asked about the average amount of time spent on planning, shopping, and prepping meals, 60% of respondents (n = 3) reported an additional hour, on average, was needed daily. This was interesting as one of the concerns frequently expressed pre-enrollment was about the amount of time that was going to be required to eat with more whole-food patterns (Table 2).Based on observations and feedback given to the dietitian, the amount of time needed decreased over the course of the program. During the first 4–6 weeks of the program, it was expressed that planning, shopping, and cooking did affect normal patterns and routine and took a considerable amount of time. There was a learning curve, for many participants, regarding incorporating PFKD into daily life and getting into a feasible routine that supported success.
- Feasibility of Self-Measurement of Health Parameters (n = 17)A total of 41% (n = 7) of respondents ranked the difficulty of taking ketone and blood sugar measurements as “not at all” and 35% (n = 6) ranked the difficulty level at 4 (scale: 1 = very difficult, 5 = not at all). The task of measuring ketones and blood sugar, once participants understood how and when to measure, did not appear to impact daily routine. The task of measuring urine pH did not appear to impact daily routines with 29% (n = 5) of respondents ranking impact at 4. The average ranking was 3.4 (scale: 1 = very difficult, 5 = not at all).
- Impact of Nutrient and Data Tracking (n = 17)The tracking and inputting of ketone levels, blood sugar, and other data seemed to be the biggest struggle for participants and most disruptive to their daily routine. When asked if entering food intake and biometrics into the Cronometer app impacted daily routine, 35% (n = 6) of participants reported it did “very much”. The average was 2.4 (scale: 1 = very much, 5 = not at all). The difficulty of data tracking should be considered when planning future clinical trials (Table 2).
- Financial ImpactSince beginning the Ren.Nu program, 53% (n = 9) of respondents reported spending “more” out of pocket on food, whereas 41% (n = 7) reported they “spend about the same”. In total, 36% (n = 4) of respondents who spent “more” indicated increased spending of USD 25–50 more per week. Equal to that, 36% (n = 4) indicated increased spending over USD 50 more per week.
Adherence
- ConfidenceIn total, 94% (n = 16) of respondents indicated they “very much” believed that what they eat affects their health (scale: 1 = does not affect, 5 = very much). A total of 88% (n = 15) of respondents also strongly believed that making changes in their diet “very much” improves how they feel (scale: 1 = does not help at all, 5 = very much). Between enrollment and program completion, there was an increase in confidence with knowing how to cook and prepare foods that preserve kidney health. At enrollment, the average confidence was 6.2 on a 10-point confident scale. The average confidence level increased to 8.4 after program completion (scale: 1 = not confident, 10 = very confident). Confidence in understanding what to eat and what to avoid to help preserve kidney function also showed a similar increase. Respondents’ confidence averaged 6.2 at enrollment and increased to an average of 8.4 during the Ren.Nu program (scale: 1 = not confident, 10 = very confident).
- Most Difficult, StrugglesConsistently, the most difficult aspect reported when following a PFKD lifestyle was eating out, either in restaurants or other homes. Eating at someone else’s house, while maintaining a PFKD, was reported as being difficult. In total, 47% (n = 8) of respondents ranked the level of difficulty as a 2 on a 5-point difficulty scale (scale: 1 = very much, 5 = not at all). Eating at restaurants also ranked high for the level of difficulty. Additionally, 35% (n = 6) of respondents reported that eating at restaurants was “very much” difficult and 24% rated the level of difficulty as a 2 for eating out (scale: 1 = very much, 5 = not at all).
- Biggest BarrierLowering protein intake, specifically animal protein, to a moderate amount was consistently expressed as the biggest barrier participants came up against with following a PFKD (Table 2).This is the opposite of previously published qualitative findings [52] that reported that reducing dietary protein intake was one of the easiest parts of an ADPKD dietary intervention which implemented a diet “to lower intake of sodium, protein, and acid precursors”. Of note, the dietary intervention lasted for 4 weeks compared to the 12-week Ren.Nu program.
- Ease of ChangeSwitching to a PFKD eating pattern, food shopping, and preparing meals were areas reported to be relatively easy. A total of 59% (n = 10) of respondents reported that switching from how they previously ate to a PFKD “took some time, but it was manageable”. In total, 35% (n = 5) of respondents found shopping for food was “not at all” difficult, and 29% (n = 5) ranked this at a score of 4. Planning and preparing meals was not perceived as difficult either. Finally, 47% (n = 8) of respondents ranked the difficulty as a 4 (scale: 1 = very difficult, 5 = not at all).
3.4. Secondary Outcomes of the Beta Test
3.5. Overall Participant Experience and Continued Support
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Lanktree, M.B.; Haghighi, A.; Guiard, E.; Iliuta, I.-A.; Song, X.; Harris, P.C.; Paterson, A.D.; Pei, Y. Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing. J. Am. Soc. Nephrol. 2018, 29, 2593–2600. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Cornec-Le Gall, E.; Alam, A.; Perrone, R.D. Autosomal Dominant Polycystic Kidney Disease. Lancet 2019, 393, 919–935. [Google Scholar] [CrossRef]
- Muller, R.U.; Benzing, T. Management of Autosomal-Dominant Polycystic Kidney Disease-State-of-the-Art. Clin. Kidney J. 2018, 11, i2–i13. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Bergmann, C.; Guay-Woodford, L.M.; Harris, P.C.; Horie, S.; Peters, D.J.M.; Torres, V.E. Polycystic Kidney Disease. Nat. Rev. Dis. Primers 2018, 4, 50. [Google Scholar] [CrossRef]
- Irazabal, M.V.; Rangel, L.J.; Bergstralh, E.J.; Osborn, S.L.; Harmon, A.J.; Sundsbak, J.L.; Bae, K.T.; Chapman, A.B.; Grantham, J.J.; Mrug, M.; et al. Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials. J. Am. Soc. Nephrol. 2015, 26, 160–172. [Google Scholar] [CrossRef]
- Yu, A.S.L.; Shen, C.; Landsittel, D.P.; Grantham, J.J.; Cook, L.T.; Torres, V.E.; Chapman, A.B.; Bae, K.T.; Mrug, M.; Harris, P.C.; et al. Long-Term Trajectory of Kidney Function in Autosomal-Dominant Polycystic Kidney Disease. Kidney Int. 2019, 95, 1253–1261. [Google Scholar] [CrossRef]
- Torres, V.E.; Chapman, A.B.; Devuyst, O.; Gansevoort, R.T.; Perrone, R.D.; Koch, G.; Ouyang, J.; McQuade, R.D.; Blais, J.D.; Czerwiec, F.S.; et al. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N. Engl. J. Med. 2017, 377, 1930–1942. [Google Scholar] [CrossRef]
- Erickson, K.F.; Chertow, G.M.; Goldhaber-Fiebert, J.D. Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Ann. Intern. Med. 2013, 159, 382–389. [Google Scholar] [CrossRef][Green Version]
- Müller, R.-U.; Haas, C.S.; Sayer, J.A. Practical Approaches to the Management of Autosomal Dominant Polycystic Kidney Disease Patients in the Era of Tolvaptan. Clin. Kidney J. 2018, 11, 62–69. [Google Scholar] [CrossRef]
- Chebib, F.T.; Perrone, R.D.; Chapman, A.B.; Dahl, N.K.; Harris, P.C.; Mrug, M.; Mustafa, R.A.; Rastogi, A.; Watnick, T.; Yu, A.S.L.; et al. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J. Am. Soc. Nephrol. 2018, 29, 2458–2470. [Google Scholar] [CrossRef][Green Version]
- Mustafa, R.A.; Yu, A.S.L. Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer? Clin. J. Am. Soc. Nephrol. 2018, 13, 1107–1109. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Pickel, L.; Iliuta, I.-A.; Scholey, J.; Pei, Y.; Sung, H.-K. Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease. Adv. Nutr. 2022, 13, 652–666. [Google Scholar] [CrossRef] [PubMed]
- Carriazo, S.; Perez-Gomez, M.V.; Cordido, A.; García-González, M.A.; Sanz, A.B.; Ortiz, A.; Sanchez-Niño, M.D. Dietary Care for ADPKD Patients: Current Status and Future Directions. Nutrients 2019, 11, 1576. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Ma, T.; Lambert, K. What Are the Information Needs and Concerns of Individuals with Polycystic Kidney Disease? Results of an Online Survey Using Facebook and Social Listening Analysis. BMC Nephrol. 2021, 22, 263. [Google Scholar] [CrossRef] [PubMed]
- Strubl, S.; Oehm, S.; Torres, J.A.; Grundmann, F.; Haratani, J.; Decker, M.; Vuong, S.; Kaur Bhandal, A.; Methot, N.; Haynie-Cion, R.; et al. Ketogenic Dietary Interventions in Autosomal-Dominant Polycystic Kidney Disease (ADPKD)—A Retrospective Case Series Study: First Insights into Feasibility, Safety and Effects. Clin. Kidney J. 2021. [Google Scholar] [CrossRef]
- Nowak, K.L.; Hopp, K. Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential. Clin. J. Am. Soc. Nephrol. 2020, 15, 577–584. [Google Scholar] [CrossRef]
- Podrini, C.; Cassina, L.; Boletta, A. Metabolic Reprogramming and the Role of Mitochondria in Polycystic Kidney Disease. Cell. Signal. 2020, 67, 109495. [Google Scholar] [CrossRef]
- Tidwell, T.R.; Soreide, K.; Hagland, H.R. Aging, Metabolism, and Cancer Development: From Peto’s Paradox to the Warburg Effect. Aging Dis. 2017, 8, 662–676. [Google Scholar] [CrossRef][Green Version]
- Magistroni, R.; Boletta, A. Defective Glycolysis and the Use of 2-Deoxy-D-Glucose in Polycystic Kidney Disease: From Animal Models to Humans. J. Nephrol. 2017, 30, 511–519. [Google Scholar] [CrossRef]
- Riwanto, M.; Kapoor, S.; Rodriguez, D.; Edenhofer, I.; Segerer, S.; Wuthrich, R.P. Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease. PLoS ONE 2016, 11, e0146654. [Google Scholar] [CrossRef][Green Version]
- Kipp, K.R.; Rezaei, M.; Lin, L.; Dewey, E.C.; Weimbs, T. A Mild Reduction of Food Intake Slows Disease Progression in an Orthologous Mouse Model of Polycystic Kidney Disease. Am. J. Physiol. Ren. Physiol. 2016, 310, F726–F731. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Warner, G.; Hein, K.Z.; Nin, V.; Edwards, M.; Chini, C.C.; Hopp, K.; Harris, P.C.; Torres, V.E.; Chini, E.N. Food Restriction Ameliorates the Development of Polycystic Kidney Disease. J. Am. Soc. Nephrol. 2016, 27, 1437–1447. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Torres, J.A.; Kruger, S.L.; Broderick, C.; Amarlkhagva, T.; Agrawal, S.; Dodam, J.R.; Mrug, M.; Lyons, L.A.; Weimbs, T. Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease. Cell Metab. 2019, 30, 1007–1023.e5. [Google Scholar] [CrossRef] [PubMed]
- Veech, R.L.; Bradshaw, P.C.; Clarke, K.; Curtis, W.; Pawlosky, R.; King, M.T. Ketone Bodies Mimic the Life Span Extending Properties of Caloric Restriction. IUBMB Life 2017, 69, 305–314. [Google Scholar] [CrossRef]
- Rojas-Morales, P.; Tapia, E.; Pedraza-Chaverri, J. Beta-Hydroxybutyrate: A Signaling Metabolite in Starvation Response? Cell. Signal. 2016, 28, 917–923. [Google Scholar] [CrossRef]
- Newman, J.C.; Verdin, E. Beta-Hydroxybutyrate: A Signaling Metabolite. Annu. Rev. Nutr. 2017, 37, 51–76. [Google Scholar] [CrossRef]
- Reed, B.; Helal, I.; McFann, K.; Wang, W.; Yan, X.D.; Schrier, R.W. The Impact of Type II Diabetes Mellitus in Patients with Autosomal Dominant Polycystic Kidney Disease. Nephrol. Dial. Transpl. 2012, 27, 2862–2865. [Google Scholar] [CrossRef][Green Version]
- Nowak, K.L.; Steele, C.; Gitomer, B.; Wang, W.; Ouyang, J.; Chonchol, M.B. Overweight and Obesity and Progression of ADPKD. Clin. J. Am. Soc. Nephrol. 2021, 16, 908–915. [Google Scholar] [CrossRef]
- Hopp, K.; Catenacci, V.A.; Dwivedi, N.; Kline, T.L.; Wang, W.; You, Z.; Nguyen, D.T.; Bing, K.; Poudyal, B.; Johnson, G.C.; et al. Weight Loss and Cystic Disease Progression in Autosomal Dominant Polycystic Kidney Disease. iScience 2022, 25, 103697. [Google Scholar] [CrossRef]
- Torres, J.A.; Rezaei, M.; Broderick, C.; Lin, L.; Wang, X.; Hoppe, B.; Cowley, B.D.; Savica, V.; Torres, V.E.; Khan, S.; et al. Crystal Deposition Triggers Tubule Dilation That Accelerates Cystogenesis in Polycystic Kidney Disease. J. Clin. Investig. 2019, 129, 4506–4522. [Google Scholar] [CrossRef][Green Version]
- Lucaya, J.; Enriquez, G.; Nieto, J.; Callis, L.; Garcia Peña, P.; Dominguez, C. Renal Calcifications in Patients with Autosomal Recessive Polycystic Kidney Disease: Prevalence and Cause. Am. J. Roentgenol. 1993, 160, 359–362. [Google Scholar] [CrossRef] [PubMed]
- Grampsas, S.A.; Chandhoke, P.S.; Fan, J.; Glass, M.A.; Townsend, R.; Johnson, A.M.; Gabow, P. Anatomic and Metabolic Risk Factors for Nephrolithiasis in Patients with Autosomal Dominant Polycystic Kidney Disease. Am. J. Kidney Dis. 2000, 36, 53–57. [Google Scholar] [CrossRef] [PubMed]
- Nishiura, J.L.; Neves, R.F.; Eloi, S.R.; Cintra, S.M.; Ajzen, S.A.; Heilberg, I.P. Evaluation of Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease Patients. Clin. J. Am. Soc. Nephrol. 2009, 4, 838–844. [Google Scholar] [CrossRef]
- Torres, V.E.; Erickson, S.B.; Smith, L.H.; Wilson, D.M.; Hattery, R.R.; Segura, J.W. The Association of Nephrolithiasis and Autosomal Dominant Polycystic Kidney Disease. Am. J. Kidney Dis. 1988, 11, 318–325. [Google Scholar] [CrossRef]
- Torres, V.E.; Wilson, D.M.; Hattery, R.R.; Segura, J.W. Renal Stone Disease in Autosomal Dominant Polycystic Kidney Disease. Am. J. Kidney Dis. 1993, 22, 513–519. [Google Scholar] [CrossRef]
- Levine, E.; Grantham, J.J. Calcified Renal Stones and Cyst Calcifications in Autosomal Dominant Polycystic Kidney Disease: Clinical and CT Study in 84 Patients. AJR Am. J. Roentgenol. 1992, 159, 77–81. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Hanna, C.; Potretzke, T.A.; Chedid, M.; Rangel, L.J.; Arroyo, J.; Zubidat, D.; Tebben, P.J.; Cogal, A.G.; Torres, V.E.; Harris, P.C.; et al. Kidney Cysts in Hypophosphatemic Rickets With Hypercalciuria: A Case Series. Kidney Med. 2022, 4, 100419. [Google Scholar] [CrossRef]
- Hanna, C.; Potretzke, T.A.; Cogal, A.G.; Mkhaimer, Y.G.; Tebben, P.J.; Torres, V.E.; Lieske, J.C.; Harris, P.C.; Sas, D.J.; Milliner, D.S.; et al. High Prevalence of Kidney Cysts in Patients with CYP24A1 Deficiency. Kidney Int. Rep. 2021, 6, 1895–1903. [Google Scholar] [CrossRef]
- Panizo, N.; Goicoechea, M.; Garcia de Vinuesa, S.; Arroyo, D.; Yuste, C.; Rincon, A.; Verdalles, U.; Ruiz-Caro, C.; Quiroga, B.; Luno, J. Chronic Kidney Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease. Nefrologia 2012, 32, 197–205. [Google Scholar] [CrossRef]
- Helal, I.; McFann, K.; Reed, B.; Yan, X.D.; Schrier, R.W.; Fick-Brosnahan, G.M. Serum Uric Acid, Kidney Volume and Progression in Autosomal-Dominant Polycystic Kidney Disease. Nephrol. Dial. Transpl. 2012, 28, 380–385. [Google Scholar] [CrossRef][Green Version]
- Ejaz, A.A.; Nakagawa, T.; Kanbay, M.; Kuwabara, M.; Kumar, A.; Garcia Arroyo, F.E.; Roncal-Jimenez, C.; Sasai, F.; Kang, D.-H.; Jensen, T.; et al. Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage. Semin. Nephrol. 2020, 40, 574–585. [Google Scholar] [CrossRef] [PubMed]
- Mejias, E.; Navas, J.; Lluberes, R.; Martinez-Maldonado, M. Hyperuricemia, Gout, and Autosomal Dominant Polycystic Kidney Disease. Am. J. Med. Sci. 1989, 297, 145–148. [Google Scholar] [CrossRef] [PubMed]
- Errasti, P.; Manrique, J.; Lavilla, J.; Rossich, E.; Hernandez, A.; Pujante, D.; Ndarabu, A.; Garcia, N.; Purroy, A. Autosomal-Dominant Polycystic Kidney Disease: High Prevalence of Graft Loss for Death-Related Malignancies and Cardiovascular Risk Factors. Transpl. Proc. 2003, 35, 1717–1719. [Google Scholar] [CrossRef]
- Kocyigit, I.; Yilmaz, M.I.; Orscelik, O.; Sipahioglu, M.H.; Unal, A.; Eroglu, E.; Kalay, N.; Tokgoz, B.; Axelsson, J.; Oymak, O. Serum Uric Acid Levels and Endothelial Dysfunction in Patients with Autosomal Dominant Polycystic Kidney Disease. Nephron Clin. Pract. 2013, 123, 157–164. [Google Scholar] [CrossRef] [PubMed]
- Tanner, G.A. Potassium Citrate/Citric Acid Intake Improves Renal Function in Rats with Polycystic Kidney Disease. J. Am. Soc. Nephrol. 1998, 9, 1242–1248. [Google Scholar] [CrossRef] [PubMed]
- Tanner, G.A.; Tanner, J.A. Citrate Therapy for Polycystic Kidney Disease in Rats. Kidney Int. 2000, 58, 1859–1869. [Google Scholar] [CrossRef]
- Tanner, G.A.; Tanner, J.A. Dietary Citrate Treatment of Polycystic Kidney Disease in Rats. Nephron Physiol. 2003, 93, P14–P20. [Google Scholar] [CrossRef]
- Kalantar-Zadeh, K.; Jafar, T.H.; Nitsch, D.; Neuen, B.L.; Perkovic, V. Chronic Kidney Disease. Lancet 2021, 398, 786–802. [Google Scholar] [CrossRef]
- Coyne, T.; Olson, M.; Bradham, K.; Garcon, M.; Gregory, P.; Scherch, L. Dietary Satisfaction Correlated with Adherence in the Modification of Diet in Renal Disease Study. J. Am. Diet. Assoc. 1995, 95, 1301–1306. [Google Scholar] [CrossRef]
- Taylor, J.M.; Hamilton-Reeves, J.M.; Sullivan, D.K.; Gibson, C.A.; Creed, C.; Carlson, S.E.; Wesson, D.E.; Grantham, J.J. Diet and Polycystic Kidney Disease: A Pilot Intervention Study. Clin. Nutr. 2017, 36, 458–466. [Google Scholar] [CrossRef][Green Version]
- Testa, F.; Marchiò, M.; Belli, M.; Giovanella, S.; Ligabue, G.; Cappelli, G.; Biagini, G.; Magistroni, R. A Pilot Study to Evaluate Tolerability and Safety of a Modified Atkins Diet in ADPKD Patients. PharmaNutrition 2019, 9, 100154. [Google Scholar] [CrossRef]
- Taylor, J.M.; Ptomey, L.; Hamilton-Reeves, J.M.; Sullivan, D.K.; Creed, C.; Carlson, S.E.; Wesson, D.E.; Grantham, J.J.; Gibson, C.A. Experiences and Perspectives of Polycystic Kidney Disease Patients Following a Diet of Reduced Osmoles, Protein, and Acid Precursors Supplemented with Water: A Qualitative Study. PLoS ONE 2016, 11, e0161043. [Google Scholar] [CrossRef] [PubMed]
- Nowak, K.L.; Murray, K.; You, Z.; Gitomer, B.; Brosnahan, G.; Abebe, K.Z.; Braun, W.; Chapman, A.; Harris, P.C.; Miskulin, D.; et al. Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies. Kidney Med. 2021, 3, 536–545.e1. [Google Scholar] [CrossRef]
- Moreno, B.; Crujeiras, A.B.; Bellido, D.; Sajoux, I.; Casanueva, F.F. Obesity Treatment by Very Low-Calorie-Ketogenic Diet at Two Years: Reduction in Visceral Fat and on the Burden of Disease. Endocrine 2016, 54, 681–690. [Google Scholar] [CrossRef] [PubMed]
- Valenzano, A.; Polito, R.; Trimigno, V.; Di Palma, A.; Moscatelli, F.; Corso, G.; Sessa, F.; Salerno, M.; Montana, A.; Di Nunno, N.; et al. Effects of Very Low Calorie Ketogenic Diet on the Orexinergic System, Visceral Adipose Tissue, and ROS Production. Antioxidants 2019, 8, 643. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Shillingford, J.M.; Piontek, K.B.; Germino, G.G.; Weimbs, T. Rapamycin Ameliorates PKD Resulting from Conditional Inactivation of Pkd1. J. Am. Soc. Nephrol. 2010, 21, 489–497. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Dong, K.; Zhang, C.; Tian, X.; Coman, D.; Hyder, F.; Ma, M.; Somlo, S. Renal Plasticity Revealed through Reversal of Polycystic Kidney Disease in Mice. Nat. Genet. 2021, 53, 1649–1663. [Google Scholar] [CrossRef]
- Unwin, D.; Unwin, J.; Crocombe, D.; Delon, C.; Guess, N.; Wong, C. Renal Function in Patients Following a Low Carbohydrate Diet for Type 2 Diabetes: A Review of the Literature and Analysis of Routine Clinical Data from a Primary Care Service over 7 Years. Curr. Opin. Endocrinol. Diabetes Obes. 2021, 28, 469–479. [Google Scholar] [CrossRef] [PubMed]
- Nowak, K.L.; You, Z.; Gitomer, B.; Brosnahan, G.; Torres, V.E.; Chapman, A.B.; Perrone, R.D.; Steinman, T.I.; Abebe, K.Z.; Rahbari-Oskoui, F.F.; et al. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J. Am. Soc. Nephrol. 2018, 29, 571–578. [Google Scholar] [CrossRef][Green Version]
- Sas, K.M.; Yin, H.; Fitzgibbon, W.R.; Baicu, C.F.; Zile, M.R.; Steele, S.L.; Amria, M.; Saigusa, T.; Funk, J.; Bunni, M.A.; et al. Hyperglycemia in the Absence of Cilia Accelerates Cystogenesis and Induces Renal Damage. Am. J. Physiol. Ren. Physiol. 2015, 309, F79–F87. [Google Scholar] [CrossRef][Green Version]
- Blijdorp, C.J.; Severs, D.; Musterd-Bhaggoe, U.M.; Gansevoort, R.T.; Zietse, R.; Hoorn, E.J.; DIPAK Consortium. Serum Bicarbonate Is Associated with Kidney Outcomes in Autosomal Dominant Polycystic Kidney Disease. Nephrol. Dial. Transpl. 2021, 36, 2248–2255. [Google Scholar] [CrossRef] [PubMed]
Demographics | |
Age, mean (SD 1) (years) | 48.3 (7.4) |
Male participants (%) | 40 |
Female participants (%) | 60 |
Caucasian/White (%) | 85 |
BMI, mean (SD 1) | 25.6 (3.9) |
Hypertension (%) | 85 |
Active treatment with tolvaptan (%) | 55 |
Active treatment with ACE inhibitor (%) | 30 |
Active treatment with Angiotensin II receptor blocker (%) | 55 |
CKD Stage | |
CKD 1 (GFR = 90 or higher) (%) | 0 |
CKD 2 (GFR = 60–89) (%) | 30 |
CKD 3 (GFR = 30–59) (%) | 65 |
CKD 4 (GFR = 15–29) (%) | 5 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bruen, D.M.; Kingaard, J.J.; Munits, M.; Paimanta, C.S.; Torres, J.A.; Saville, J.; Weimbs, T. Ren.Nu, a Dietary Program for Individuals with Autosomal-Dominant Polycystic Kidney Disease Implementing a Sustainable, Plant-Focused, Kidney-Safe, Ketogenic Approach with Avoidance of Renal Stressors. Kidney Dial. 2022, 2, 183-203. https://doi.org/10.3390/kidneydial2020020
Bruen DM, Kingaard JJ, Munits M, Paimanta CS, Torres JA, Saville J, Weimbs T. Ren.Nu, a Dietary Program for Individuals with Autosomal-Dominant Polycystic Kidney Disease Implementing a Sustainable, Plant-Focused, Kidney-Safe, Ketogenic Approach with Avoidance of Renal Stressors. Kidney and Dialysis. 2022; 2(2):183-203. https://doi.org/10.3390/kidneydial2020020
Chicago/Turabian StyleBruen, Diana M., Jacob J. Kingaard, Meg Munits, Clarissa S. Paimanta, Jacob A. Torres, Jessianna Saville, and Thomas Weimbs. 2022. "Ren.Nu, a Dietary Program for Individuals with Autosomal-Dominant Polycystic Kidney Disease Implementing a Sustainable, Plant-Focused, Kidney-Safe, Ketogenic Approach with Avoidance of Renal Stressors" Kidney and Dialysis 2, no. 2: 183-203. https://doi.org/10.3390/kidneydial2020020